LinkedIn Image

Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia

Meeting Overview

Expand your understanding of AML targeted therapy options and how cytogenetics influences treatment decisions with this interactive satellite symposium. Initial discussion will focus on AML subgroups classification. From there, options in initial therapy and relapsed or refractory disease will be featured. Finally, new targeted options will be examined in detail. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

This engaging meeting will provide a foundation for further exploration of new treatment options in newly-diagnosed and relapsed/refractory disease.

Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia is a prIME Oncology satellite symposium to be held at the 22nd Congress of the European Hematology Association.

Agenda

 08.00 Welcome, introduction, and quiz questions
Miguel Sanz, MD
08.05 Examining genetics and genomics in AML in 2017
Elli Papaemmanuil, PhD
08.20 Quiz questions
08.25 Personalizing initial therapy in AML
Francesco Lo Coco, MD
08.45 Q & A
08.50 Quiz questions
08.55 What’s on the horizon for relapsed/refractory AML?
Lisa Pleyer, MD
09.15 Q & A
09.20 Quiz questions
09.25 A deeper dive into AML subgroups
Miguel Sanz, MD
09.45 Q & A
09.50 Quiz questions
09.55 Key points
Miguel Sanz, MD
10.00 Adjourn

Faculty

CHAIR
  • Miguel Sanz, MDValencia University Medical School
    University Hospital La Fe
    Valencia, Spain
FACULTY
  • Francesco Lo Coco, MDUniversity Tor Vergata
    Rome, Italy
  • Elli Papaemmanuil, PhDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Lisa Pleyer, MDSalzburg Cancer Research Institute
    Salzburg, Austria

Target Audience

The proposed educational activity is specifically designed to meet the needs of hematologists, oncologists, pathologists, and other healthcare professionals involved in the treatment of patients with AML.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Compare current AML classification systems and the role that cytogenetics plays in them
  • Describe molecularly-defined subtypes of AML
  • Evaluate current initial therapeutic strategies in newly-diagnosed AML based on patient and disease characteristics
  • Identify novel agents being investigated in relapsed/refractory AML

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Register Now

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Date and Location

Thursday, 22 June 2017
08.00 – 10.00

Room N103
IFEMA – Feria de Madrid
Av. Partenón, 5
Madrid, Spain

Printed Materials

Printed Materials

Provider

This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

ACCME-commendation-full-color

prIME Oncology designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME Practice

gCMEp-FINAL-logo-1

Support

This educational activity is supported by grants from Celgene, Helsinn Healthcare SA, and Novartis Oncology.

Sunshine Act/EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

I Agree